Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00004688 | Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms | completed | Phase 2 | 35 | Emory UniversityOTHER | 0 | Mar 25, 2015 | clinicaltrials |
| NCT01582516 | Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00179907 | A Phase I/II Study of the Photon Radiosurgery System | completed | Phase 1 / Phase 2 | 35 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 2, 2015 | clinicaltrials |
| NCT01115491 | A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 32 | Hoffmann-La RocheINDUSTRY | 1 | Dec 8, 2014 | clinicaltrials |
| NCT00024570 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 60 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00525525 | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma(AVF4120s) | completed | Phase 2 | 74 | University of California, San FranciscoOTHER | 1 | Nov 14, 2014 | clinicaltrials |
| NCT01006044 | Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection | completed | Phase 2 | 26 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00616005 | Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide | completed | Phase 2 | 41 | Duke UniversityOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT01380782 | BIBF 1120 for Recurrent High-Grade Gliomas | completed | Phase 2 | 37 | Patrick Y. Wen, MDOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT00941460 | Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma(DIRECTOR) | completed | Phase 2 | 105 | Prof. Dr. Wolfgang WickOTHER | 3 | Aug 15, 2014 | clinicaltrials |
| NCT00613093 | Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma | completed | Phase 2 | 67 | Duke UniversityOTHER | 1 | Jul 9, 2014 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00238303 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00641706 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00597402 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | completed | Phase 2 | 125 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00677716 | Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 41 | Peregrine PharmaceuticalsINDUSTRY | 2 | Apr 24, 2014 | clinicaltrials |
| NCT00397072 | Epothilone in Recurrent Glioblastoma Patients | completed | Phase 2 | 15 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00979017 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | completed | Phase 2 | 41 | Katy PetersOTHER | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00657267 | Dose-Intense Temozolomide in Recurrent Glioblastoma | completed | Phase 2 | 58 | Patrick Y. Wen, MDOTHER | 1 | Mar 14, 2014 | clinicaltrials |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | completed | Phase 2 | 56 | Duke UniversityOTHER | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00337883 | A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) | completed | Phase 2 | 110 | Genentech, Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00575887 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | completed | Phase 2 | 25 | Marmara UniversityOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00921167 | A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas | completed | Phase 2 | 32 | Clinical Research Center for Solid Tumor, KoreaOTHER | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00431561 | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma | completed | Phase 2 | 141 | Isarna Therapeutics GmbHINDUSTRY | 6 | Dec 3, 2013 | clinicaltrials |
| NCT00305656 | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00612430 | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | completed | Phase 2 | 59 | Duke UniversityOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00672243 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00039494 | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | completed | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00016328 | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00014170 | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00613028 | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | completed | Phase 2 | 23 | Duke UniversityOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00870181 | ADV-TK Improves Outcome of Recurrent High-Grade Glioma(HGG-01) | completed | Phase 2 | 47 | Huazhong University of Science and TechnologyOTHER | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00597493 | Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00939991 | Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 48 | Katy PetersOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00501891 | Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00612339 | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | completed | Phase 2 | 41 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00671970 | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | completed | Phase 2 | 57 | Duke UniversityOTHER | 1 | May 13, 2013 | clinicaltrials |
| NCT00058097 | Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00615927 | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | completed | Phase 2 | 64 | Duke UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01100177 | Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients | completed | Phase 2 | 12 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 11, 2013 | clinicaltrials |
| NCT00354913 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00190424 | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | completed | Phase 2 | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 13, 2012 | clinicaltrials |
| NCT00606008 | A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00409214 | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma | completed | Phase 2 | 18 | Light Sciences OncologyINDUSTRY | 1 | Nov 16, 2012 | clinicaltrials |
| NCT01251484 | BIBF 1120 in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 25 | Ulrik LassenOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT00624728 | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)(GLIO-TEP) | completed | Phase 1 / Phase 2 | 21 | University Hospital, BordeauxOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT01285414 | Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 5 | Myrexis Inc.INDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00412542 | Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00036569 | A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Feb 13, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Mar 25, 2015source: clinicaltrials